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Abstract
Introduction: Acquisition of mesenchymal characteristics confers to breast cancer (BC) cells the capability of
invading tissues different from primary tumor site, allowing cell migration and metastasis. Regulators of the
mesenchymal-epithelial transition (MET) may represent targets for anticancer agents. Accruing evidence supports
functional implications of choline phospholipid metabolism in oncogene-activated cell signaling and differentiation.
We investigated the effects of D609, a xanthate inhibiting phosphatidylcholine-specific phospholipase C (PC-PLC)
and sphingomyelin synthase (SMS), as a candidate regulator of cell differentiation and MET in the highly metastatic
BC cell line MDA-MB-231.
Methods: PC-PLC expression and activity were investigated using confocal laser scanning microscopy (CLSM),
immunoblotting and enzymatic assay on human MDA-MB-231 compared with MCF-7 and SKBr3 BC cells and a
nontumoral immortalized counterpart (MCF-10A). The effects of D609 on PC-PLC and SMS activity, loss of
mesenchymal markers and changes in migration and invasion potential were monitored in MDA-MB-231 cells by
enzymatic assays, CLSM, immunoblotting and transwell chamber invasion combined with scanning electron
microscopy examinations. Cell proliferation, formation and composition of lipid bodies and cell morphology were
investigated in D609-treated BC cells by cell count, CLSM, flow-cytometry of BODIPY-stained cells, nuclear magnetic
resonance and thin-layer chromatography.
Results: PC-PLC (but not phospholipase D) showed 2- to 6-fold activation in BC compared with nontumoral cells,
the highest activity (up to 0.4 pmol/μg protein/min) being detected in the poorly-differentiated MDA-MB-231 cells.
Exposure of the latter cells to D609 (50 μg/mL, 24-72 h) resulted into 60-80% PC-PLC inhibition, while SMS was
transiently inhibited by a maximum of 21%. These features were associated with progressive decreases of
mesenchymal traits such as vimentin and N-cadherin expression, reduced galectin-3 and milk fat globule EGF-
factor 8 levels, b-casein formation and decreased in vitro cell migration and invasion. Moreover, proliferation arrest,
changes in cell morphology and formation of cytosolic lipid bodies typical of cell differentiation were induced by
D609 in all investigated BC cells.
Conclusions: These results support a critical involvement of PC-PLC in controlling molecular pathways responsible
for maintaining a mesenchymal-like phenotype in metastatic BC cells and suggests PC-PLC deactivation as a means
to promote BC cell differentiation and possibly enhance the effectiveness of antitumor treatments.
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Introduction
Differentiation markers expressed by a primary breast
cancer (BC) are currently profiled to guide prognosis
and clinical decisions. Poorly differentiated tumors are
held to be more aggressive and predictive of a less
favorable response to treatment. There is increasing
interest in regulators of the oncogenic epithelial-
mesenchymal transition (EMT) and its reciprocal pro-
cess, mesenchymal-epithelial transition (MET), for eluci-
dation of the mechanisms underlying tumor progression
and metastasis and the possible identification of new
targets for cancer treatment [1].
The discovery of an abnormal choline phospholipid
metabolism as the hallmark of BC and other cancers
(reviewed in [2-5]) stimulated investigations on the pos-
sible role of phosphatidylcholine (PtdCho) cycle
enzymes as potential indicators of tumor response and
novel therapy targets [5-8]. Biochemical, genomic, and
proteomic assays showed upregulation of choline kinase
(ChoK) in BC and in epithelial ovarian cancer (EOC)
cell lines [9-11]. RNA interference-mediated ChoK
knockdown has been reported to exert anti-proliferative
effects and induce cell differentiation in BC cells [12].
We recently showed potent increases of both ChoK and
PtdCho-specific phospholipase C (PC-PLC) activities in
EOC cells compared with non-tumoral counterparts
[10,11]. PC-PLC isoforms responsible for PtdCho hydro-
lysis into phosphocholine and diacylglycerol (DAG) have
been isolated but not yet cloned from mammalian
sources. However, accruing evidence points to multiple
implications of this enzyme in cell signaling through
mitogen-activated protein kinase (MAPK) and onco-
gene-activated protein kinase pathways, programmed
cell death, activation of immune cells, and stem cell dif-
ferentiation ([13-19] and references therein). Further-
more, we reported direct evidence on PC-PLC activation
and changes in subcellular localization of this enzyme in
cancer [20,21] and non-tumoral receptor-activated
mammalian cells [13,15-17]. In particular, selective PC-
PLC accumulation was detected on the plasma mem-
brane of EOC cells [20], human epidermal growth factor
receptor 2 (HER2)-overexpressing BC cells [21], mito-
gen-stimulated fibroblasts [13], and cytokine-activated
human natural killer cells [15-17]. The competitive PC-
PLC inhibitor tricyclodecan-9-yl-potassium xanthate
(D609) [22] used at the dose of 50 μg/mL (188 μM)
blocked EOC cell proliferation [11] and prevented these
cells from entering the S phase under growth factor sti-
mulation [20]. Moreover, PC-PLC was found to associ-
ate with the HER2 receptor in raft domains of the
plasma membrane of HER2-overexpressing BC cells
[21]. In these cells, D609-induced PC-PLC inhibition
resulted in HER2 receptor downregulation, together
with that of its heterodimers with cognate members of
the epidermal growth factor receptor family, by interfer-
ing with receptor internalization, degradation, and recy-
cling. Overall, this body of evidence suggests the
existence of regulatory links between PC-PLC activity,
membrane receptor expression, and cancer cell
proliferation.
On the other hand, at much higher doses (at least 500
μM), D609 not only inhibited cell proliferation but also
reduced cell viability, eventually inducing apoptosis in
the metastatic cell line MDA-MB-435 [23]. These effects
were attributed to intracellular ceramide accumulation,
as a result of D609-induced inhibition of sphingomyelin
synthase (SMS) and activation of de novo ceramide
synthesis.
In the present work, we report direct evidence of a
sixfold constitutive PC-PLC upregulation in the poorly
differentiated, highly metastatic BC cell line MDA-MB-
231 compared with a non-tumoral counterpart, MCF-
10A. Significant but lower increases in PC-PLC content
and activity were also found in other BC cell lines
(SKBr3 and MCF-7).
The rates of PC-PLC and SMS activity were measured
in MDA-MB-231 cells in either the presence or absence
of D609 (50 μg/mL). Special traits of MET and BC cell
differentiation - such as decreased expression of vimen-
tin and N-cadherin; downmodulation of molecules criti-
cally involved in tumor progression, such as galectin-3
and milk fat globule-epidermal growth factor 8 (MFG-
E8); and production of b-casein - were detected in
D609-treated MDA-MB-231 cells, together with long-
standing and irreversible reduction of in vitro cell moti-
lity and invasion capabilities. Typical features of cell dif-
ferentiation, such as proliferative arrest with
maintenance of cell viability, changes in cell morphol-
ogy, and formation of lipid bodies, were induced by
D609 in all of the investigated BC cells.
Materials and methods
Cells
The human BC cell lines MDA-MB-231 (triple-negative:
ER-, PgR-, and HER2-), SKBr3 (ER-, PgR-, and HER2+),
and MCF-7 (ER+, PgR+, and HER2-) and the non-
tumorigenic immortalized human mammary epithelial
cell line MCF-10A were supplied by American Type
Culture Collection (Manassas, VA, USA). The cells were
cultured, as previously described [21], in either the pre-
sence or absence of D609 (Sigma-Aldrich, St. Louis,
MO, USA).
Antibodies and reagents
Rabbit polyclonal antibodies (Abs) raised against bacter-
ial (Bacillus cereus) PC-PLC and selectively cross-
Abalsamo et al. Breast Cancer Research 2012, 14:R50
http://breast-cancer-research.com/content/14/2/R50
Page 2 of 16
reacting with mammalian PC-PLC were obtained in our
laboratory [24] in accordance with a modification of the
method originally described by Clark and colleagues
[25] and characterized as reported [13,15]. Alexa
Fluor®-633-conjugated phalloidin, 4,4-difluoro-1,3,5,7,8-
pentamethyl-4-bora-3a, 4a-diaza-s-indacene (Bodipy
493/503), Bodipy-TR (BTR) ceramide, and the secondary
Abs Alexa Fluor®-594 F(ab)2 fragments of goat anti-rab-
bit and goat anti-mouse IgG (H+L) were purchased
from Molecular Probes Inc. (now part of Invitrogen
Corporation, Carlsbad, CA, USA); mouse anti-b-actin
and anti-vimentin Abs from Sigma-Aldrich; rabbit poly-
clonal anti-HER2, anti-E-cadherin, and anti-N-cadherin
and mouse monoclonal anti-MFG-E8 from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA); monoclonal
anti-galectin-3 and anti-b-casein Abs from Abcam
(Cambridge, UK); and horseradish peroxidase-conju-
gated goat anti-mouse and goat anti-rabbit IgG from
Bio-Rad Laboratories, Inc. (Hercules, CA, USA). Chemi-
cals were from Sigma-Aldrich unless otherwise specified.
Confocal laser scanning microscopy and flow cytometry
analyses
For immunofluorescence analyses, cells were seeded in
24-well cluster plates onto 12-mm cover glasses. After
48 hours of culture in complete medium, cells were
treated with or without D609 for different times, fixed
in 3% paraformaldehyde (30 minutes at 4°C), permeabi-
lized by Triton X-100 (0.5%, 10 minutes at room tem-
perature), and then stained at 37°C with Bodipy 493/
503, followed by Alexa Fluor®-633-conjugated phalloidin
or by the primary and Alexa Fluor®-594-conjugated sec-
ondary Abs. The cover glasses were finally mounted on
the microscope slide with Vectashield anti-fade mount-
ing medium containing 4’ 6-diamidino-2-phenylindole
(DAPI) (Vector Laboratories, Burlingame, CA, USA).
Confocal laser scanning microscopy (CLSM) observa-
tions were performed with a Leica TCS SP2 AOBS
apparatus (Leica, Wetzlar, Germany), as described [20],
by using excitation spectral laser lines at 405, 488, 594,
and 633 nm. CLSM images were obtained by three-
dimensional reconstruction of three or four optical
sections.
For flow cytometry analyses, cells were detached from
the substrate in phosphate-buffered saline ethylenedia-
minetetraacetic acid (PBS-EDTA) (5 mM). The fluores-
cence intensity of Bodipy 493/503 was measured on log-
scale by using a FACScan (BD Biosciences, San Jose,
CA, USA) apparatus. Apoptosis was evaluated by mea-
suring the modulation of phosphatidylserine externaliza-
tion by using Annexin V-biotin (Bender MedSystems
GmbH, Vienna, Austria) followed by Alexa Fluor®-488-
conjugated streptavidin (Molecular Probes Inc.). After
treatment with D609 (50 μg/mL) for 24, 48, and 72
hours, cells were stained with Annexin V-biotin and
488-conjugated streptavidin and then analyzed by flow
cytometry.
Western blot analyses
According to our previously described procedure [20],
protein expression was evaluated in total lysates (30 μg
of proteins) from cells treated with or without D609 in
complete medium.
In vitro PC-PLC, phospholipase D, and sphingomyelin
synthase activity assays
PC-PLC and phospholipase D (PLD) activity rates were
determined in whole-cell lysates by using the Amplex
Red assay kit (Molecular Probes Inc.) and a procedure
described by the manufacturer and adapted by Spadaro
and colleagues [16,20]. Changes of SMS activity were
measured as described by Meng and colleagues [26] and
adapted by Cecchetti and colleagues [17].
Cell proliferation
MDA-MB-231, SKBr3, and MCF-7 cells were plated in
six-well plates at a density of 1 × 105 cells per well for
SKBr3 and 5 × 104 cells for MDA-MB-231 and MCF-7.
After 48 hours of culture, cells were incubated with or
without D609 for different time points. Afterwards, cells
were detached from the substrate in PBS-EDTA (5
mM), and cell proliferation was evaluated by hemacyt-
ometer counting of viable Trypan blue-excluding cells.
Nuclear magnetic resonance spectroscopy
Intact cells were counted, washed three times in PBS,
centrifuged at 600g, and resuspended in PBS-D2O (700
μL) before transfer to 5-mm nuclear magnetic resonance
(NMR) tubes (20 × 106 cells). 1H NMR analyses (25°C)
were performed at 400 or 700 MHz (Bruker BioSpin
Avance 400 or 700; Bruker BioSpin, Karlsruhe, Ger-
many). Analyses of 1H NMR spectra and peak area
deconvolution were performed as previously described
[27].
Lipid extraction and high-performance thin-layer
chromatography analyses
Total lipid extracts obtained according to Folch and col-
leagues [28] were analyzed by thin-layer chromatogra-
phy (TLC) by using cholesterol, cholesteryl esters, and
triacylglycerols as standards [27]. Analyses were per-
formed by staining the lipid bands with 2% copper acet-
ate solution in 8% phosphoric acid and subsequent
heating at 120°C for 15 minutes. The relative quantifica-
tion of individual lipid classes was obtained by using the
‘Quantity One’ Bio-Rad software program (Bio-Rad
Laboratories, Inc.) and normalized to the number of
cells.
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Transwell chamber migration and invasion assays
The effects of D609 on the migration and invasive
potentials of MDA-MB-231 cells were analyzed by a
transwell chamber assay [29] by using inserts (8.0-μm
pore, Falcon; BD, Franklin Lakes, NJ, USA) which stood
in six-well plates (Costar, now part of Corning Life
Sciences, Acton, MA, USA). In a first series of experi-
ments, MDA-MB-231 cells were seeded in the transwell
chambers either with or without D609 (50 μg/mL) and
allowed to migrate to the lower side of the filter for 20
hours at 37°C. In a second series of experiments, MDA-
MB-231 cells were first treated with or without D609
(50 μg/mL) for 24, 48, and 72 hours and subsequently
detached and seeded in the transwell chambers for 20-
hour assays in the absence of the inhibitor.
For the invasion assays, Matrigel™ (Sigma-Aldrich)
was diluted to 1 mg/mL in serum-free Dulbecco’s modi-
fied Eagle’s medium (DMEM) and 250 μL was placed
into the insert which stood in each well of the six-well
plate. The inserts and the plate were incubated over-
night at 4°C. The following day, cells were harvested
and suspended in serum-free DMEM at a concentration
of 1 × 106 cells per milliliter. The cell suspension was
added to each insert, and 3 mL of DMEM containing
10% fetal bovine serum was added to the well under-
neath the insert. Cells were incubated at 37°C for 20
hours. After this time period, the inner side of the insert
was wiped with a wet swab to remove the cells while
the outer side of the insert was gently rinsed with PBS
and stained with 0.25% crystal violet for 10 minutes,
rinsed again, and then allowed to dry. The inserts were
then viewed under the microscope. The detection of
cells that had invaded through the membrane was per-
formed under a computer-assisted color camera-
equipped Nikon Optiphot microscope (Nikon Corpora-
tion, Tokyo, Japan), and the percentage of the area
occupied by migrated cells (or their number) was ana-
lyzed by dedicated software (Optilab; Graftek Imaging
Inc., Austin, TX, USA). The analysis was performed on
18 fields of each sample. The procedure for carrying out
motility assays was identical to that used for invasion
assays with the exception that inserts were not coated
with Matrigel™.
Scanning electron microscopy
Examinations were performed, as previously described
[30], on a Cambridge Stereoscan 360 scanning electron
microscope (Cambridge Instruments, Cambridge, UK).
Statistical analysis
Data were analyzed by using GraphPad Software version
3.03 (GraphPad Software, Inc., La Jolla, CA, USA). Sta-
tistical significance of differences was determined by
one-way analysis of variance (ANOVA) or by Student t
test, as specified. Differences were considered significant
at a P value of less than 0.05.
Results
PC-PLC overexpression and activation in MDA-MB-231
cells
Differential PC-PLC expression and activity were mea-
sured in MDA-MB-231 cells and compared with those of
the other investigated BC cells and the non-tumoral
counterpart by using CLSM analyses, Western blot, and
biochemical assays. Figure 1a shows the intracellular dis-
tribution of PC-PLC in fixed and permeabilized cells,
stained with the anti-PC-PLC Ab. The highly metastatic
MDA-MB-231 cell line showed the highest PC-PLC con-
tent, distributed in both nuclear and cytoplasmic com-
partments, including the inner filamentous structures
directed from perinuclear area to the cell periphery. A
qualitatively similar intracellular PC-PLC distribution
was exhibited by SKBr3 and MCF-7 cell lines in which,
however, the overall PC-PLC content appeared to be
lower than that of MDA-MB-231 cells. Only a few PC-
PLC-positive granules were instead detected in MCF-10A
cells, where they were concentrated mainly in perinuclear
areas and were practically absent in intranuclear regions.
Western blot analyses of total cell lysates (Figure 1b)
allowed detection of a PC-PLC isoform with an apparent
molecular weight (Mr) of 66 kDa, which is in agreement
with previous studies by our group and other groups on
a number of different mammalian systems
[13,15-18,20,21,24,25,31]. Densitometric analyses con-
firmed that the MDA-MB-231 cells expressed the high-
est PC-PLC content, and the factor of increase was 6.0
± 1.6 (± standard deviation) in comparison with the
non-tumoral counterpart. All BC cells showed a higher
PC-PLC protein expression in comparison with MCF-
10A cells (one-way ANOVA P < 0.002), but the factors
of increase were lower in SKBr3 (4.9 ± 0.9) and MCF-7
(3.4 ± 0.7) than in MDA-MB-231 cells. As shown in Fig-
ure 1c, Amplex Red assays on total lysates from cells
harvested at early confluence also showed a 6.3 ± 1.2-
fold increase in the PC-PLC activity in MDA-MB-231
cells in comparison with the non-tumoral counterpart,
whereas the factors of increase were lower for the other
BC cells (3.4 ± 0.9 for SKBr3 and 3.3 ± 0.6 for MCF-7).
By contrast, the PLD activity was not significantly differ-
ent among BC and non-tumoral cells (Additional file 1).
Altogether, these results showed that the highest PC-
PLC upregulation occurred in the poorly differentiated
MDA-MB-231 cells.
Cell proliferation arrest in MDA-MB-231 cells exposed to
D609
The absolute PC-PLC activity of untreated (control, or
CTR) MDA-MB-231 cells increased in the log-phase of
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growth from 0.2 to 0.4 pmol/μg protein per minute
between 24 and 72 hours (early confluence) and
decreased thereafter (Figure 2a). Cell exposure to D609
(50 μg/mL, 188 μM) inhibited the PC-PLC activity by
60% at 24 to 48 hours and by 80% at 72 hours.
Continuous exposure of MDA-MB-231 cells to this
dose of D609 induced a long-standing cell proliferation
arrest up to at least 144 hours (Figure 2b). Similar anti-
proliferative effects were found for D609-treated SKBr3
and MCF-7 cells (Additional file 2, panels a and b). The
D609-induced inhibition of cancer cell growth was not
due to general cytotoxicity, because the number of dead
cells was practically maintained at the same levels in BC
and in their control cultures (Figure 2b and Additional
file 2a and b). The difference in the percentage of dead
cells in untreated compared with treated BC cell cul-
tures was therefore due to D609-induced inhibition of
cell proliferation rather than to an increase in cell mor-
tality. Moreover, measurement of the percentages of
Annexin V-positive cells showed that, at this dose, D609
did not exert any substantial apoptotic effect on any of
the investigated BC cells (Figure 2c and Additional file
2c and d).
A massive loss of cell viability was instead detected in
MDA-MB-231 cell cultures exposed to much higher
D609 doses (at least 500 μM), as shown in panels a and
b of Additional file 3. In cells treated for 48 hours, the
percentage of dead cells increased from 12.5% ± 4.5% at
the dose of 188 μM to 69.3% ± 14.1% at 500 μM and
88.9% ± 8.1% at 750 μM, compared with 5.1% ± 2.7% in
control cells. Similar differential levels were detected at
72 hours. At the dose of D609 henceforth used through-
out this study (50 μg/mL), the SMS activity was inhib-
ited by only 21% at 48 hours and 5% at 72 hours
(Figure 2d). Therefore, the inhibition of SMS, compared
with that of PC-PLC, was threefold lower at 48 hours
and 16-fold lower at 72 hours (Figure 2e). Overall, these
results showed that, at the dose of 50 μg/mL, the most
relevant inhibitory effect of D609 on MDA-MB-231
cells was targeted against PC-PLC.
Figure 1 Overexpression and activation of PC-PLC in human breast cancer cell lines. (a) Confocal laser scanning microscopy examinations
(three-dimensional reconstruction images) of fixed human breast cancer cells (MCF-7, SKBr3, and MDA-MB-231) and non-tumoral immortalized
mammary epithelial cells (MCF-10A) that were stained for intracellular PC-PLC detection (pseudo-color gray). Nuclei were stained with DAPI
(blue). Scale bars, 20 μm. (b) Representative Western blot analyses (of three independent experiments) of cell lysates show PC-PLC and HER2
protein expression (actin was used as a quantitative loading control). (c) Relative PC-PLC activity (presented as mean ± standard deviation, n = 3)
in cancer versus non-tumoral cells at early confluence. Student t test, *P = 0.007, **P < 0.003, ***P < 0.0001; one-way analysis of variance of
tumoral versus non-tumoral cells, P < 0.0001. DAPI, 4’,6-diamidino-2-phenylindole; HER2, human epidermal growth factor receptor 2; PC-PLC,
phosphatidylcholine-specific phospholipase C.
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Formation of cytoplasmic lipid bodies and changes of cell
morphology in D609-treated MDA-MB-231 cells
The maturation of breast cells is typically characterized
by the formation of cytoplasmic lipid bodies and pro-
duction of the milk protein b-casein [32]. CLSM ana-
lyses showed that only a few lipid vacuoles were present
in MDA-MB-231 cells (Figure 3a) cultured in complete
medium (CTR) and stained with Bodipy 493/503
(green), a fluorescent hydrophobic molecule that selec-
tively localizes to neutral lipid aggregates [33]. However,
when these cells were incubated with D609 (50 μg/mL),
lipid bodies were already detected at 24 hours and their
number increased at 48 to 72 hours and remained at
high levels thereafter. Furthermore, during D609 incuba-
tion, cells progressively underwent morphological
changes by retracting the cytoplasm toward the nucleus
(rounded morphology at 24 to 72 hours) and displaying
a flattened morphology with expansion of the cytoplasm
at longer times, a characteristic feature of mature breast
cells [32,34]. Flow cytometry analyses of Bodipy-stained
cells showed up to threefold to fourfold increases in the
mean fluorescence intensity of D609-treated MDA-MB-
231 cells in comparison with the untreated control, and
the maximum was at 48 to 72 hours (Figure 3b). Similar
morphological changes and induction of lipid bodies
were observed in D609-treated SKBr3 and MCF-7 cells
(Additional files 4 and 5). Western blot analyses showed
formation of b-casein, which already occurred in MDA-
MB-231 cells at 24 hours of exposure to D609 (Figure
3c).
The intracellular formation of isotropically tumbling
lipid bodies was confirmed by 1H NMR spectra of intact
MDA-MB-231 cells incubated for 48 hours with D609
(Figure 3d), in which a fourfold increase was measured
Figure 2 PC-PLC and SMS activity inhibition and cell growth arrest in MDA-MB-231 cells exposed to D609 (50 μg/mL). (a) Absolute PC-
PLC activity (mean ± SD, n = 4) measured in total lysates of MDA-MB-231 cells harvested after exposure to D609 (gray columns) in comparison
with untreated cells (CTR, black columns). Student t test, *P ≤ 0.04, **P ≤ 0.02, ***P = 0.0002; ns, not significant. (b) Cell counts (mean ± SD, n =
3) of MDA-MB-231 cells incubated in the absence (black square, viable cells; white square, dead cells) or presence (black circle, viable cells; white
circle, dead cells) of D609. Cells were seeded (S) 48 hours before treatment, which started at t = 0 (arrow). (c) Percentage of Annexin V-positive
cells in D609-treated and the respective CTR cells. (d) Relative SMS activity detected in MDA-MB-231 cells incubated in the absence (CTR) or
presence of D609 for the indicated times. Lipid extracts were added with BTR-ceramide, and the formation of the SMS product, BTR-
sphingomyelin (BTR-SM), was detected by thin-layer chromatography and quantified by densitometric analysis (representative example of two
independent experiments). (e) Comparison of the percentages of PC-PLC (gray) and SMS (white) inhibition induced in MDA-MB-231 cells by
exposure to D609 for 48 or 72 hours. BTR, Bodipy-TR; PCho, phosphocholine; PC-PLC, phosphatidylcholine-specific phospholipase C; SD, standard
deviation; SMS, sphingomyelin synthase.
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Figure 3 Formation of cytoplasmic lipid bodies and production of b-casein in MDA-MB-231 cells exposed to D609. (a) Confocal laser
scanning microscopy analyses (three-dimensional reconstruction images) of MDA-MB-231 cells cultured in the absence (CTR) or presence of
D609 (50 μg/mL) for the indicated times and stained with Bodipy 493/503 (green). Morphological changes of actin cytoskeleton were monitored
by phalloidin-633 staining (red); nuclei are reported in blue (DAPI). Scale bar, 20 μm. (b) Histogram showing the fold increase in Bodipy 493/503
fluorescence intensity measured by flow cytometry in D609-treated MDA-MB-231 cells in comparison with CTR (mean ± standard deviation, n =
3). (c) Changes in b-casein expression detected by Western blot in MDA-MB-231 cells after incubation with D609 for the indicated times (actin as
loading control). (d) Representative proton nuclear magnetic resonance (1H NMR) spectrum of intact MDA-MB-231 cells incubated for 48 hours
in the absence (black) or presence (green) of D609, showing increases in -(CH2)n- (1.30 ppm) and = CH-CH = (5.34 ppm) signals of mobile lipids
in D609-treated cells (details in inserts). Asterisk indicates unidentified signal of commercial phosphate-buffered saline buffer. (e) Thin-layer
chromatography analysis of total lipid extracts of D609-treated MDA-MB-231 cells in comparison with CTR. Fold increases were as follows:
triacylglycerols (TAG), 1.8 ± 0.1 at 48 hours and 1.8 ± 0.8 at 72 hours (n = 3); cholesteryl esters (CE), 1.4 ± 0.1 at 48 hours and 1.7 ± 0.5 at 72
hours; cholesterol (CHOL), 1.0 ± 0.1 at 48 hours and 1.1 ± 0.1 at 72 hours. Phospholipids (PL) were not significantly altered. CTR, control; DAPI,
4’,6-diamidino-2-phenylindole; ppm, parts per million.
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in the area of the resonance at 1.30 parts per million
(ppm), typical of saturated -(CH2)n- segments of mobile
lipid fatty acyl chains ([27] and references therein).
Moreover, a clear-cut increase of the -CH = CH- reso-
nance (at 5.34 ppm) indicated that these chains were
partially unsaturated.
TLC analyses of lipid extracts showed an average 1.8-
fold increase in triacylglycerols and 1.4- to 1.7-fold
increases in cholesteryl esters at 48 to 72 hours of cell
exposure to D609, whereas cholesterol and the overall
phospholipid contents remained unaltered (Figure 3e).
Overall, these experiments showed that exposure to
D609 induced the following in the metastatic MDA-
MB-231 cells: intracellular accumulation of cytoplasmic
lipid bodies, expression of b-casein, and morphological
changes typical of breast cell maturation.
Decrease of mesenchymal traits and markers of
tumorigenesis in D609-treated MDA-MB-231 cells
A typical feature of the mesenchymal phenotype is the
overexpression of vimentin, an intermediate filament
associated with increased invasive and metastatic poten-
tial of BC cells [35]. As shown in Figure 4a, vimentin
expression was high in MDA-MB-231 cells but was
barely detectable in MCF-10A cells. A progressive
decrease of vimentin was detected in MDA-MB-231
cells, starting from 24 hours of exposure to D609, and
33% ± 4% of cells became vimentin-negative at 96 hours
(Figure 4a) and 50% ± 17% at 144 hours (not shown).
The simultaneous formation of cytoplasmic lipid bodies
was confirmed by Bodipy staining (Figure 4a, green).
Partial reversal of the mesenchymal-like phenotype in
D609-treated MDA-MB-231 cells was further supported
by a strong decrease of N-cadherin (by 74% ± 4% at 24
hours, Student t test P = 0.01, and 75% ± 9% at 120
hours, P ≤ 0.005), whereas E-cadherin maintained prac-
tically undetectable levels throughout cell incubation
with D609 (Figure 4b).
Exposure of MDA-MB-231 cells to D609 also resulted
in decreased galectin-3 (Figure 4c), a protein implicated
in cancer cell growth, adhesion, angiogenesis, and meta-
static potential [36,37]. The reduction in galectin-3
expression became substantial only at long times of D609
exposure, and decreases of 51% ± 13% at 96 hours and
65% ± 16% at 120 hours were observed. Lastly, a substan-
tial reduction in the expression of MFG-E8, reputed to
be a promoter of tumorigenesis in triple-negative BC
[38,39], was detected in D609-treated MDA-MB-231
cells, and average decreases of 61% ± 3% at 48 hours and
83% ± 4% at 120 hours were observed (Figure 4c).
Unlike the content of MFG-E8 and galectin-3, that of
PC-PLC was maintained substantially unaltered in
MDA-MB-231 cells exposed to D609. Independent
Western blot experiments, performed by using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as
a loading control, showed that the actin level was also
kept unmodified (data not shown). Overall, these results
support the view that D609-induced PC-PLC inhibition
was associated in MDA-MB-231 cells with the loss of
some markers typical of mesenchymal phenotype and
tumorigenesis.
Decrease of migration and invasion potential in D609-
treated MDA-MB-231 cells
The quantitative analysis of migration and invasion
potential was performed on membranes stained with
crystal violet, as described in Materials and methods.
The analyses were carried out by estimating either the
percentage of area occupied by the cells (Figure 5) or
the number of cells that migrated to the lower side of
the filter (Additional file 6).
In the first series of experiments described in Materi-
als and methods, cells were seeded in transwell cham-
bers and allowed to migrate across the filter or invade
the Matrigel™ for 20 hours, either with or without
D609 (50 μg/mL). Quantitative analyses showed that the
presence of D609 significantly inhibited both cell moti-
lity and invasion (see histograms in Figure 5a and Addi-
tional file 6a). Qualitative examinations by scanning
electron microscopy showed that the migrating or
invading untreated cells (CTR) adopted a polygonal and
flat morphology when they adhered to the upper side of
the filter and moved individually across the pores in
either the absence (Figure 6a) or presence (Figure 6b) of
Matrigel™. Exposure to D609 induced morphological
changes on the migrating cells, which frequently
appeared less flattened and even roundish (Figure 6a).
In invasion assays, D609-treated cells showed a mark-
edly round morphology and clustered together (Figure
6b). These features are known to reflect the reorganiza-
tion of actin microfilaments in viable migrating or
invading cells, as demonstrated by previous fluorescence
microscopy studies (for example, [40]). As shown in Fig-
ure 6b, in the presence of D609, very few migrating cells
were observed on the lower side of the filter. Matrigel™
film, in fact, appeared intact, suggesting that D609
inhibited both the cell movement and the matrix
proteolysis.
In the second series of experiments, cells were sepa-
rately incubated with D609 for 24, 48, and 72 hours,
washed, and then transferred to the transwell chambers
in the absence of D609. Significantly reduced migration
and invasion capabilities were confirmed for the D609-
treated cells in comparison with untreated controls (Fig-
ure 5c and 5d and Additional file 6c and d), providing
evidence that these effects were not reverted during the
20-hour migration and invasion assays performed in the
absence of the inhibitor.
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Discussion
This study reports the first evidence of a high (sixfold)
overexpression and activation of PC-PLC (but not PLD)
in a highly metastatic, triple-negative BC cell line
(MDA-MB-231) in comparison with a non-tumoral
counterpart. Substantial, though lower, upregulation of
PC-PLC was also detected in the luminal-like MCF-7
and in the HER2-positive SKBr3 cell line.
A strong (60% to 80%) PC-PLC inhibition was induced
in MDA-MB-231 cells by 24- to 72-hour exposure to
D609 at the dose of 50 μg/mL. Under these conditions,
these and other BC cells underwent proliferation arrest
in the absence of apoptosis, along with morphological
changes typical of cell differentiation.
Figure 7 shows some basic links between pathways of
biosynthesis and catabolism of PtdCho and sphingomye-
lin, together with their relations with two major biologi-
cal effects: membrane synthesis and apoptosis. At the
D609 dose used in our study, inhibition of SMS was 3-
to 16-fold lower than that of PC-PLC at 48 to 72 hours
of cell exposure to this agent. At doses that were 2.5- to
5.3-fold higher, D609 has been reported to induce apop-
tosis in the highly metastatic MDA-MB-435 carcinoma
cell line, likely because of activation of ceramide
Figure 4 Effects of D609 on the expression of vimentin and other differentiation markers in MDA-MB-231 cells. (a) Vimentin expression
detected by Western blot in MDA-MB-231 and MCF-10A cells (actin, loading control). The expression and distribution of vimentin (red) were
evaluated by confocal laser scanning microscopy (three-dimensional reconstruction images) in D609-treated or untreated (CTR) MDA-MB-231
cells. Lipid body formation was monitored by Bodipy 493/503 staining (green). Nuclei are reported in blue (DAPI). Scale bar, 20 μm. (b, c)
Changes in protein expression of N-cadherin, E-cadherin, PC-PLC, MFG-E8, and galectin-3, evaluated by Western blot analyses of MDA-MB-231
cells incubated with D609 (actin, loading control). Experiments in panels (a-c) were independently repeated three times with similar results. CTR,
control; DAPI, 4’,6-diamidino-2-phenylindole; PC-PLC, phosphatidylcholine-specific phospholipase C.
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synthase and stronger SMS inhibition with consequent
accumulation of ceramides [23]. A massive loss of cell
viability was also detected in our study in BC cell cul-
tures of different subtypes exposed to similarly high
doses of D609.
In regard to possible effects exerted by D609 on the
activity of other enzymes, previous analyses of reaction
mixtures showed that D609 did not directly inhibit PLD,
phosphatidylinositol-specific phospholipase C (PI-PLC),
phospholipase A2 [22], or sphingomyelinase [24]. How-
ever, an increase, rather than inhibition, of PLD-
mediated PtdCho hydrolysis has been reported in lysates
of osteoblastic osteosarcoma cells exposed to D609 at
the dose of 50 μg/mL [41]. This effect, possibly due to
mechanisms taking place in the cell to compensate for
PC-PLC inhibition, was not associated with changes in
the cell differentiation status.
The major finding of this study was that the strong
inhibitory effect exerted by a non-apoptotic dose of
D609 on PC-PLC activity in MDA-MB-231 cells was
associated with the acquisition by these cells of a series
of features typical of the MET process and cell differen-
tiation, such as (a) progressive depletion of vimentin
and N-cadherin expression, (b) significant reduction of
in vitro cell migratory and invasive capabilities, (c) for-
mation of cytoplasmic lipid bodies and production of
the milk protein b-casein, and (d) decrease in the levels
of two markers of cancer cell aggressiveness: MFG-E8
and galectin-3.
These results and their interpretation also provided a
reason to further investigate the reversibility of the
effects induced by the PC-PLC inhibitor on BC cell dif-
ferentiation. Our study showed that, although the D609-
induced MET was not complete (E-cadherin was not
Figure 5 Quantitative analysis of the migration and invasion potential of MDA-MB-231 cells. The analysis was performed after staining
with crystal violet the transwell chamber inserts to detect the cells migrated to the lower side of the porous membranes in the absence
(migration) or presence (invasion) of Matrigel™. White columns represent control cells, and gray columns represent D609-treated cells. (a)
Percentage of area occupied by migrating and invading cells in the absence or presence of D609. (b) Representative membranes containing
cells that migrated in the absence or presence of Matrigel™. Examples of migration (c) and invasion (d) of MDA-MB-231 cells that were first
treated with D609 (50 μg/mL) for 24, 48, and 72 hours, were subsequently detached, and were finally seeded in the transwell chambers and
allowed to migrate in the absence of the inhibitor. CTR, control.
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formed), some of the effects induced by this agent, such
as reduced migration and invasion capabilities, were not
reverted when D609 was withdrawn from the medium.
This body of evidence supports the views that (a) a
high PC-PLC activity is associated with a poorly differ-
entiated BC cell phenotype and (b) PC-PLC inhibition
likely contributes to the molecular mechanisms leading
these cells across a partial MET and cell differentiation.
PC-PLC activity as a possible mechanistic regulator of
EMT/MET switch in metastatic breast cancer cells
EMT is a major multistep process in BC progression,
comprising the acquisition of mesenchymal features
associated with dissolution of the epithelial integrity, cell
proliferation, increased migration and local invasion,
and, ultimately, distant metastasis [35,42-44]. Less-differ-
entiated stem-like properties typical of the mesenchymal
Figure 6 Qualitative analysis of the migration and invasion potential of MDA-MB-231 cells. Scanning electron microscopy observations
were performed at the end of the 20-hour assays in the absence (migration) (a) or presence of Matrigel™ (invasion) (b) on cells treated with or
without D609 (50 μg/mL). The imaging was performed on both the upper and lower sides of the filter. On the upper side, adherent cells are
visible. On the lower side, cells that migrated through the pores of the membrane are depicted. Scale bars, 100 μm. CTR, control.
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status [45] are reported for highly malignant BC cells
which, compared with epithelial cells, commonly present
higher vimentin and N-cadherin and low, if any, E-cad-
herin expression [35]. These molecular events lead to a
less rigid cytoskeleton, reduced cell-cell contact, acquisi-
tion of cell-elongated shape, cell invasiveness, and
metastasis. Our study shows that a substantial portion
of these features were lost in MDA-MB-231 cells in
which continuous exposure to D609 induced a strong
and persistent PC-PLC inhibition. Although vimentin
and N-cadherin losses were not associated with any rise
in E-cadherin expression, a late marker of the MET pro-
cess, it is worth noting that other characteristic features
of BC cell differentiation (cell growth arrest, formation
of intracellular lipid bodies, and b-casein production)
were distinctly detected during D609 treatment.
The high level of MFG-E8 detected in the metastatic
MDA-MB-231 cells is in agreement with a recent report
showing that this avb3-5 integrin ligand is a potential
metastasis-associated tumor biomarker of triple-negative
BC cells [39]. The decrease in MFG-E8 expression in
D609-treated MDA-MB-231 cells, reported here,
deserves further investigations in light of an increased
sensitivity to cisplatin reported for triple-negative BC
cells following p63 and MFG-E8 knockdown by siRNA
(short interfering RNA) transfection [39].
Additional support for a possible role of PC-PLC inhi-
bition in enhancing the sensitivity of metastatic BC cells
to drug-induced cytotoxicity may be provided by the
decrease of galectin-3 in D609-treated MDA-MB-231
cells, also reported here. In fact, inhibition of galectin-3
by a synthetic agent was recently reported to increase
the sensitivity of a pulmonary BC metastasis to taxol-
induced apoptosis in vitro and in vivo [46].
Possible molecular mechanisms sustaining the role of PC-
PLC activity as a regulator of breast cancer cell
differentiation
Although the molecular bases of EMT and MET have
not been fully elucidated, inter-linked transduction path-
ways and signaling molecules, including growth factors,
tyrosine kinase receptors, and Ras effector-activated
MAPK and phoshoinositide 3 kinase/AKT/mammalian
target of rapamycin (PI3K/AKT/mTOR) axes, are
reputed to be involved in key processes such as control
of cell proliferation, shape remodeling, motility, and
metastasis [47,48]. The strong activation of PC-PLC in
the highly metastatic MDA-MB-231 cells, reported here,
and the loss of mesenchymal traits crucial to cytoskele-
tal reorganization, cell motility, and invasion in BC cells
exposed to a PC-PLC inhibitor suggest that the PC-PLC
activity status may play a pivotal role in the EMT/MET
switch.
As schematically represented in Figure 8, PC-PLC
works at the crossroad of major cell signaling pathways
responsible for cell proliferation, motility, and
Figure 7 Schematic representation of major links between pathways of biosynthesis and catabolism of phosphatidylcholine (PtdCho)
and sphingomyelin (SM) and their relationships with membrane synthesis and apoptosis. The dose-dependent effects of D609 on
phospholipase C (PLC) and sphingomyelin synthase (SMS) inhibition and on stimulation of ceramide synthase are described in the Discussion
section. CCT, phosphocholine-cytidylyl transferase; CDP-Cho, cytidine 5’-diphosphocholine; Cho, free choline; ChoK, choline kinase; DAG,
diacylglycerol; PCho, phosphocholine; SMase, sphingomyelinase.
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differentiation. In fact, a PC-PLC-mediated DAG release
from PtdCho may contribute to a long-lasting activation
of protein kinase C (PKC), a family of isoenzymes
involved in different functions, including regulation of
BC cell morphology, motility, and invasiveness [49]. A
decrease in the DAG pool as a result of PC-PLC inhibi-
tion could therefore lead to reduced cell motility due to
partial PKC deactivation and subsequent cytoskeletal
rearrangements at the cell-leading edge, similarly to the
effects of DAG depletion detected in cancer cells
exposed to PI-PLC-g inhibitors [50].
Furthermore, a switch in the PC-PLC activation status
could interfere with the biological effects of the two inter-
linked MAPK and PI3K/AKT/mTOR axes. The PC-PLC-
mediated DAG production can, in fact, be partly converted
by DAG kinase (DAGK) into phosphatidate, a potent
mitogen reported to stimulate MAPK and to act as an
antagonist of rapamycin at the mTORC-1 complex-bind-
ing site [51-53]. PC-PLC-driven changes in the phosphati-
date content can, therefore, be expected to influence (a)
the proliferative/anti-proliferative effects exerted by these
signaling pathways, (b) the migratory/anti-migratory
effects exerted by rapamycin-sensitive downhill targets of
mTOR at the level of the G1-to-S transition and cell moti-
lity [48], and (c) the balance of anti-apoptotic effects
exerted by antagonists of cell death.
Figure 8 Proposed role of PC-PLC in piloting cell signaling effects on breast cancer cell proliferation and differentiation. Metabolites/
second messengers: CDP-Cho, cytidine 5’-diphosphocholine; Cho, free choline; DAG, diacylglycerol; IP3, inositol (1,4,5)-trisphosphate; PA,
phosphatidate; PCho, phosphocholine; PIP2, phosphatidylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PtdCho,
phosphatidylcholine. Inhibitors: R, rapamycin and its analogs. Enzymes/protein kinases: AKT/PKB, AKT/protein kinase B; CCT, phosphocholine-
cytidylyl transferase; CDP-Cho, cytidine 5’-diphosphocholine; ChoK, choline kinase; DAGK, diacylglycerol kinase; MAPK, mitogen-activated protein
kinase; mTOR, mammalian target of rapamycin; PAP, phosphatidate phosphohydrolase; PC-PLC, phosphatidylcholine-specific phospholipase C;
PCT, phosphocholine diacylglycerol transferase; P-ERK, phosphorylated extracellular signal-regulated kinase; PI3K, phosphoinositide 3-kinase; PI-
PLC, phosphoinositide-specific phospholipase C; PKC, protein kinase C; PLD, phospholipase D; PTEN, phosphatase and tensin homolog. Black
arrows indicate chemical reactions, dotted green arrows represent stimulation or other link, blue dotted arrows represent molecular transport or
transfer to a different site, and solid gray arrows point to biological effects.
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Conclusions
The results reported here support the view that a PC-
PLC activation/deactivation switch may act as a regula-
tor of molecular mechanisms responsible for redirecting
EMT to MET and inducing cell differentiation in BC
cells. This hypothesis suggests the possible use of PC-
PLC as a new target for anti-cancer therapy, which may
leave non-neoplastic tissues unaffected. Preclinical in
vivo investigations to evaluate the role of PC-PLC inhi-
bitors to enhance the effectiveness of therapies against
poorly differentiated BCs, including triple-negative BCs,
are, therefore, warranted.
Additional material
Additional file 1: Relative PC-specific phospholipase D (PLD) activity
in breast cancer cells. PLD activity was measured by Amplex Red assay
in breast cancer (BC) cell lines (MCF-7, SKBr3 and MDA-MB-231)
compared with the human nontumoral mammary epithelial cells MCF-
10A, all harvested at early confluence. Relative fold changes in BC cell
PLD activity were normalized to the activity of MCF-10A cells, set to 1.
Histograms represent the mean ± SD (n = 3). No significant differences
were found in the relative rates of PLD in all investigated cell lines.
Additional file 2: Proliferation arrest induced by D609 (50 μm/mL)
in SKBr3 and MCF-7 cells. (A) and (B) Cell counts (mean ± SD, n = 3)
of SKBr3 and MCF-7 cells incubated in absence (black square, viable cells;
white square, dead cells) or presence of D609 (black circle, viable cells;
white circle, dead cells). Cells were seeded (S) 48 h before treatment,
which started at t = 0 (arrow). (C) and (D) Percentages of Annexin V-
positive cells in D609-treated and the respective CTR cells.
Additional file 3: Effects of different doses of D609 on cell growth
and viability of MDA-MB-231 cells. Cells were incubated with different
doses of D609 (188 μM, (corresponding to 50 μg/mL), 500 μM and 750
μM) for 48 h or 72 h. Cell proliferation was measured by cell count. Cell
viability was assessed by trypan blue excluding test (experiments
performed in triplicate).
Additional file 4: Induction of intracellular lipid bodies in SKBr3
cells following exposure to the PC-PLC inhibitor D609. CLSM
analyses (three-dimensional reconstruction images) of cells exposed to
D609 (50 μg/mL) for the indicated time intervals, then fixed and stained
with the lipid probe BODIPY 493/503 (green) for the detection of
cytoplasmic lipid bodies and with phalloidin-633 (red) for monitoring
morphological changes of actin cytoskeleton. Nuclei are reported in blue
(DAPI). The corresponding control cell cultures are reported in the panels
indicated by ‘CTR’ and ‘CTR 72 h’. Scale bar, 20 μm. Histogram on the
bottom panel: fold-increase of BODIPY 493/503 fluorescence intensity
measured by flow cytometry in D609-treated SKBr3 cells compared with
untreated controls (mean ± SD values of three independent
experiments).
Additional file 5: Induction of intracellular lipid bodies in MCF-7
cells following exposure to the PC-PLC inhibitor D609. CLSM
analyses (three-dimensional reconstruction images) of cells exposed to
D609 (50 μg/mL) for the indicated time intervals, then fixed and stained
with the lipid probe BODIPY 493/503 (green) for the detection of
cytoplasmic lipid droplets and with phalloidin-633 (red) for monitoring
morphological changes of actin cytoskeleton. Nuclei are reported in blue
(DAPI). The corresponding control cell cultures are reported in the panels
indicated by ‘CTR’ and ‘CTR 120 h’. Scale bar, 20 μm. Histogram on the
bottom panel: fold-increase of BODIPY 493/503 fluorescence intensity
measured by flow cytometry in D609-treated MCF-7 cells compared with
untreated controls (mean ± SD values of three independent
experiments).
Additional file 6: Quantitative analysis of the migration and
invasion potential of MDA-MB-231 cells. The analysis was performed
after staining with crystal violet the cells migrated to the lower side of
the porous membranes, in the absence (migration assay) or in the
presence (invasion assay) of Matrigel™™. White columns: control cells;
gray columns: D609-treated cells. (A) The number of both migrating and
invading cells (calculated as the mean of cell counts evaluated in six
72.000 ⌠m2 fields for each sample) significantly decreased when the
transwell chamber invasion assay was performed in the presence of
D609. (B) Images of the lower side of filters containing cells migrated in
the absence or in the presence of Matrigel™™. (C-F) The effect of D609
proved to be irreversible: the inhibition of migration (C) and (E) and
invasion (D, F) was also observed when MDA-MB-231 cells were first
treated with D609 (50 ⌠g/ml) for 24, 48 and 72 h, subsequently detached
and seeded in the transwell chambers and allowed to migrate in
absence of the inhibitor. All experiments were calculated in triplicate.
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